# A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants

> **NCT04476303** · PHASE1 · COMPLETED · sponsor: **BeyondBio Inc.** · enrollment: 88 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** BEY2153

## Key facts

- **NCT ID:** NCT04476303
- **Lead sponsor:** BeyondBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-27
- **Primary completion:** 2021-11-23
- **Final completion:** 2021-11-23
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2025-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476303, "A Study to Evaluate the Pharmacokinetics and Safety of BEY2153 in Healthy Participants". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04476303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*